UY25436A1 - STATIN-MMP INHIBITOR COMBINATIONS - Google Patents
STATIN-MMP INHIBITOR COMBINATIONSInfo
- Publication number
- UY25436A1 UY25436A1 UY25436A UY25436A UY25436A1 UY 25436 A1 UY25436 A1 UY 25436A1 UY 25436 A UY25436 A UY 25436A UY 25436 A UY25436 A UY 25436A UY 25436 A1 UY25436 A1 UY 25436A1
- Authority
- UY
- Uruguay
- Prior art keywords
- mmp inhibitor
- statin
- inhibitor combinations
- combination
- ldl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una combinación de un compuesto de estatina,que se sabe que causa una reducción en los niveles plasmáticos de colesterol lipoproteínas de baja densidad (ldl),y un inhibidor de mmp,que reduce la ruptura de tejidos conectivos. La combinación es útil para tratar trastornos vasculares y prevenir la insuficiencia cardiaca.The invention relates to a combination of a statin compound, known to cause a reduction in plasma levels of low-density lipoprotein cholesterol (LDL), and an mmp inhibitor, which reduces the breakdown of connective tissues. The combination is useful for treating vascular disorders and preventing heart failure.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7826598P | 1998-03-17 | 1998-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25436A1 true UY25436A1 (en) | 2001-10-25 |
Family
ID=22142950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25436A UY25436A1 (en) | 1998-03-17 | 1999-03-16 | STATIN-MMP INHIBITOR COMBINATIONS |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1063991A1 (en) |
| JP (1) | JP2002506818A (en) |
| KR (1) | KR20010041916A (en) |
| AR (1) | AR018113A1 (en) |
| AU (1) | AU1591699A (en) |
| BR (1) | BR9815745A (en) |
| CA (1) | CA2309588A1 (en) |
| CO (1) | CO5070670A1 (en) |
| GT (1) | GT199900039A (en) |
| HN (1) | HN1999000029A (en) |
| MY (1) | MY140504A (en) |
| NZ (1) | NZ505994A (en) |
| PA (1) | PA8469001A1 (en) |
| PE (1) | PE20000348A1 (en) |
| SV (1) | SV1999000026A (en) |
| UY (1) | UY25436A1 (en) |
| WO (1) | WO1999047138A1 (en) |
| ZA (1) | ZA992106B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| EP1827448A1 (en) | 2004-12-15 | 2007-09-05 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| EP1948599A1 (en) * | 2005-11-08 | 2008-07-30 | Ranbaxy Laboratories Limited | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| EP2310417A4 (en) * | 2008-07-11 | 2012-01-11 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA000514B1 (en) * | 1995-11-02 | 1999-10-28 | Варнер-Ламберт Компани | Method of regulating lipoprotein profile of blood plasma in a mammal and pharmaceutical composition to perform thereof |
| DK0901466T3 (en) * | 1996-05-17 | 2002-02-18 | Warner Lambert Co | Biphenylsulfonamide-matriksmetalloproteinase inhibitors |
| BR9714385A (en) * | 1996-12-09 | 2000-05-16 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilation |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GT199800126A (en) * | 1997-08-29 | 2000-01-29 | COMBINATION THERAPY. |
-
1998
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/en active Pending
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Application Discontinuation
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/en not_active Application Discontinuation
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
- 1998-11-20 NZ NZ505994A patent/NZ505994A/en unknown
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/en not_active Application Discontinuation
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/en unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/en not_active Application Discontinuation
- 1999-03-16 CO CO99016109A patent/CO5070670A1/en unknown
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/en unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/en not_active Application Discontinuation
- 1999-03-16 GT GT199900039A patent/GT199900039A/en unknown
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/en unknown
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/en unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9815745A (en) | 2000-11-14 |
| AU1591699A (en) | 1999-10-11 |
| CA2309588A1 (en) | 1999-09-23 |
| MY140504A (en) | 2009-12-31 |
| AR018113A1 (en) | 2001-10-31 |
| SV1999000026A (en) | 2000-01-18 |
| PE20000348A1 (en) | 2000-05-22 |
| ZA992106B (en) | 1999-09-30 |
| KR20010041916A (en) | 2001-05-25 |
| PA8469001A1 (en) | 2002-09-17 |
| GT199900039A (en) | 2000-09-06 |
| EP1063991A1 (en) | 2001-01-03 |
| HN1999000029A (en) | 1999-09-29 |
| WO1999047138A1 (en) | 1999-09-23 |
| NZ505994A (en) | 2003-10-31 |
| CO5070670A1 (en) | 2001-08-28 |
| JP2002506818A (en) | 2002-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25268A1 (en) | INHIBITION OF LIPOPROTEIN OXIDATION | |
| DK0840732T3 (en) | Substituted benzolactam compounds as substance P antagonists | |
| PT971713E (en) | USE OF COLINESTERASE INHIBITORS FOR TREATMENT OF ATENTION DISORDERS | |
| EA199800667A1 (en) | NEW PHENANTRIDINES | |
| CY1106915T1 (en) | Bile acid separator and sterol absorption inhibitors and vasoconstrictor therapies | |
| UY25322A1 (en) | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS TO TREAT AND PREVENT INFLAMMATORY DISEASES AND ATEROSCLEROSIS | |
| UY25299A1 (en) | STATIN-CARBOXYALKYL ETHER COMBINATIONS | |
| EA199900837A1 (en) | METHOD OF USING CYCLOOXIGENASE-2 INHIBITORS TO PREVENT CARDIOVASCULAR DISORDERS | |
| BR9911440A (en) | Composition for the prevention and / or treatment of osteoporosis and changes due to menopause syndrome | |
| CO4970724A1 (en) | COMBINATION THERAPY | |
| BR0212252A (en) | Methods to Reduce Hypertension and Heart Failure in a Mammal | |
| ECSP034782A (en) | DERIVATIVES OF MERCAPTOACETILAMIDE, PROCEDURE FOR PREPARATION AND USE | |
| SI1427409T1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
| IL110943A0 (en) | Compositions for the treatment of skin disorders | |
| EE200100155A (en) | A method of treating atherosclerosis using an a2 inhibitor and a combination thereof | |
| CL2004000366A1 (en) | USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION. | |
| PT1032414E (en) | COMBINATION OF AN INHIBITOR OF THE ANGIOTENSIN CONVERSATION ENZYME AND A DIURETIC FOR THE TREATMENT OF MICROCIRCULATORY DISTURBACTIONS | |
| WO2005046797A3 (en) | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions | |
| NZ503962A (en) | ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis | |
| PT1109571E (en) | METHODS OF TREATMENT OF HYPERTENSION AND COMPOSITIONS FOR USE IN THESE METHODS | |
| UY25436A1 (en) | STATIN-MMP INHIBITOR COMBINATIONS | |
| BR9916255A (en) | Compound, pharmaceutical composition, use of a compound, and methods of treating a condition in which thrombin inhibition is required and for the preparation of compounds | |
| BR9713522A (en) | Method of using cyclooxygenase-2 inhibitors as antiangiogenic agents. | |
| DK0885005T3 (en) | Use of dehydroepiandrosterone and aromatase inhibitors in the manufacture of a medicament for the treatment of a relative and absolute androgen deficiency in men | |
| EA199901043A1 (en) | PHARMACEUTICAL TRANSFERASE INHIBITORS IN A COMBINATION WITH HMG-CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20110104 |